Targeting Molecular Pathways in Intracranial Metastatic Disease
The discovery and clinical application of agents targeting pivotal molecular pathways in malignancies such as lung, breast, renal cell carcinoma, and melanoma have led to impressive improvements in clinical outcomes. Mutations in epidermal growth factor receptor (EGFR), and rearrangements of anaplas...
Main Authors: | Vyshak Alva Venur, Justine V. Cohen, Priscilla K. Brastianos |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2019-03-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fonc.2019.00099/full |
Similar Items
-
Editorial: Contemporary Management of Intracranial Metastatic Disease
by: Sunit Das, et al.
Published: (2019-08-01) -
Clinical Biomarkers for Early Identification of Patients with Intracranial Metastatic Disease
by: Karolina Gaebe, et al.
Published: (2021-11-01) -
Clinical correlates and prognostic value of different metastatic sites in patients with malignant melanoma of the skin: a SEER database analysis
by: Omar Abdel-Rahman
Published: (2018-02-01) -
Brain Metastases from Colorectal Cancer: A Systematic Review of the Literature and Meta-Analysis to Establish a Guideline for Daily Treatment
by: Sophie Müller, et al.
Published: (2021-02-01) -
The Underlying Biology and Therapeutic Vulnerabilities of Leptomeningeal Metastases in Adult Solid Cancers
by: Matthew Dankner, et al.
Published: (2021-02-01)